Search Within

Jae Hong Park

Formats
  1. Meeting Abstract (218)
  2. Journal Article (126)
  3. Review (18)
  4. Research Letter (7)
  5. Guidelines (3)
  6. Book Section (2)
  7. Correspondence (2)
  8. Editorial (2)
Groups
  1. Adult Leukemia (378)
  2. Center for Hematologic Malignancies (378)
  3. Department of Medicine (378)
  4. Hematologic Malignancies, Division of (378)
  5. GSK Faculty (188)
  6. Hematologic Malignancies Research (145)

More Groups

People
  1. Renier Brentjens (105)
  2. Isabelle Riviere (85)
  3. Maria Palomba (84)
  4. Michel Sadelain (84)
  5. Martin Tallman (81)
  6. Miguel-Angel Perales (72)

More People

Years
  1. 2025 (26)
  2. 2024 (38)
  3. 2023 (38)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (24)

More Years

Publications
  1. Blood (147)
  2. Journal of Clinical Oncology (31)
  3. Blood Advances (14)
  4. Haematologica (9)
  5. Leukemia and Lymphoma (9)
  6. Transplantation and Cellular Therapy (9)

More Publications

Publishers
  1. American Society of Hematology (161)
  2. Elsevier Inc. (35)
  3. American Society of Clinical Oncology (33)
  4. Nature Publishing Group (30)
  5. Taylor & Francis Group (12)
  6. American Association for Cancer Research (10)

More Publishers

Results (378)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CAR T-cell therapy and the pharmacology of managing cytokine release syndrome
    Review

    Park, J.; King, A. C.
    Journal of the Advanced Practitioner in Oncology (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save
  • A phase 2 study of actinium-225 ((225)Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML)
    Meeting Abstract

    Atallah, E.; Berger, M.; Jurcic, J.; Roboz, G.; Tse, W.; Mawad, R.; Rizzieri, D.; Begna, K.; Orozco, J.; Craig, M.; more...
    Journal of Medical Imaging and Radiation Sciences (2019)

    Fulltext@MSK | Save
  • ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
    Review

    Lee, D. W.; Santomasso, B. D.; Locke, F. L.; Ghobadi, A.; Turtle, C. J.; Brudno, J. N.; Maus, M. V.; Park, J. H.; Mead, E.; Pavletic, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
    Journal Article

    King, A. C.; Pappacena, J. J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
    Leukemia Research (2019)

    Fulltext@MSK | Save
  • Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms
    Journal Article

    Arcila, M. E.; Yu, W.; Syed, M.; Kim, H.; Maciag, L.; Yao, J.; Ho, C.; Petrova, K.; Moung, C.; Salazar, P.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
    Review

    Short, N. J.; Jabbour, E.; Albitar, M.; de Lima, M.; Gore, L.; Jorgensen, J.; Logan, A. C.; Park, J.; Ravandi, F.; Shah, B.; more...
    American Journal of Hematology (2019)

    Fulltext@MSK | Save
  • Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents
    Meeting Abstract

    Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL
    Meeting Abstract

    Park, J. H.; Lee, J. O.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Vemuri, S.; Abdel-Wahab, O. I.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save